A cell-permeable compound that potently, selectively and reversibly inhibits Akt1/Akt2/Akt3 activity.
Product Details
| Alternative Name: | Akti-1/2, Isozyme-selective Akt inhibitor VIII, 1,3-Dihydro-1-(1-((4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one, Imidazoquinoxaline 16h |
| |
| Formula: | C34H29N7O |
| |
| MW: | 551.6 |
| |
| CAS: | 612847-09-3 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | Off-white to yellow powder. |
| |
| Solubility: | Soluble in DMSO. |
| |
| Shipping: | Ambient |
| |
| Short Term Storage: | -20°C |
| |
| Long Term Storage: | -80°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Carboxyl group-modified α-lactalbumin induces TNF-α-mediated apoptosis in leukemia and breast cancer cells through the NOX4/p38 MAPK/PP2A axis: J.T. Chiou, et al.; Int. J. Biol. Macromol.
187, 513 (2021),
Abstract;
Comparative Analysis of CTRP-Mediated Effects on Cardiomyocyte Glucose Metabolism: Cross Talk between AMPK and Akt Signaling Pathway: L. Li, et al.; Cells
10, 905 (2021),
Abstract;
